Retatrutide, a novel dual agonist of the GLP-1 target and glucose-dependent insulinotropic polypeptide (GIP) target, is exhibiting promising outcomes in early patient studies. Recent inquiry suggests https://geniusbookmarks.com/story21350664/retatrutide-emerging-research-and-possible-medical-uses